The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report

Aim: to learn the role of docetaxel in non-castrate resistant prostate cancer patient. Methods: literature search was conducted to find relevant study comparing the combination of docetaxel and androgen deprivation therapy (ADT) to ADT alone in non-castrate resistant prostate cancer using PubMed, Co...

Full description

Bibliographic Details
Main Authors:	Fakhri Rahman, Harrina Erlianti Rahardjo, Stefanus Cahyo Ariwicaksono, Hafizar Hafizar, Muhammad Gozali Arif Sembiring, Rendy Andika, Richman Patandung, Septiani Hidianingsih, Stevano Lucianto Hotasi
Format:	Article
Language:	English
Published:	Interna Publishing 2017-04-01
Series:	Acta Medica Indonesiana
Subjects:	Docetaxel androgen deprivation therapy evidence-based case report metastatic prostate cancer overall survival
Online Access:	http://www.actamedindones.org/index.php/ijim/article/view/244

Similar Items

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
by: Li Q, et al.
Published: (2019-12-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment
by: Yingying Zhang, et al.
Published: (2022-04-01)

Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
by: Whi-An Kwon, et al.
Published: (2019-05-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
by: Koji Hatano, et al.
Published: (2023-10-01)

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
by: Seonggyu Byeon, et al.
Published: (2020-11-01)

Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
by: Kenichi Hata, et al.
Published: (2022-11-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Docetaxel-induced radiation recall dermatitis
by: EG Kandemir, et al.
Published: (2005-01-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
by: Narita Shintaro, et al.
Published: (2012-01-01)

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer
by: Takehiko Nakasato, et al.
Published: (2020-03-01)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
by: Sotaro Chikamatsu, et al.
Published: (2022-03-01)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
by: Sang Eun Yoon, et al.
Published: (2019-05-01)

Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta
by: Emilio Jesús Alegre del Rey, et al.
Published: (2017-07-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
by: Thiago S. Lima, et al.
Published: (2022-06-01)

Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients
by: Cheng-Li Kao, et al.
Published: (2015-12-01)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
by: Hu L, et al.
Published: (2020-06-01)

Docetaxel-related interstitial pneumonitis
by: Wang CJ, et al.
Published: (2015-12-01)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
by: Huang Y, et al.
Published: (2022-11-01)

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
by: Aurelia H. M. deVries Schultink, et al.
Published: (2019-04-01)

Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
by: Leandro Blas, et al.
Published: (2022-01-01)

Docetaxel for High-Grade Mucoepidermoid Carcinoma of the Lung
by: Hui-Ching Wang, et al.
Published: (2015-09-01)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
by: Jie Xu, et al.
Published: (2018-10-01)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
by: Kyungchan Min, et al.
Published: (2020-04-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
by: Zhuifeng Guo, et al.
Published: (2022-08-01)

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis
by: Ying Zhang, et al.
Published: (2025-01-01)

Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer
by: Gabrielle Robin, et al.
Published: (2024-08-01)

Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer
by: Zhang X, et al.
Published: (2019-04-01)

Weekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer
by: Hyeong Dong Yuk, et al.
Published: (2024-12-01)

Docetaxel Micelles: A New Formulation to Diminish Hypersensitivity Reactions
by: Lanlan Xiang, et al.
Published: (2025-02-01)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01)

Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer
by: Shan-Shan Wang, et al.
Published: (2024-10-01)